Drug Trial Radar · NCT06016036
SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease
Last checked: Nov 20, 2026Latest source record: Aug 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
156
Actual
Start
Dec 8, 2020
Primary completion
Oct 8, 2021
Study completion Feb 21, 2022
Sponsor
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase 3 randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of SAL-0951 in CKD-anemia patients in Non-dialysis, comprising 8 weeks of double-blind treatment period followed by an open-label treatment period, making up a total of 27 weeks.
Conditions
- Renal Anemia in Non-dialysis Chronic Kidney Disease
Interventions
SAL-0951Drug
SAL-0951: 1. initial phase:4mg QD for 8 weeks 2. subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks
PlaceboDrug
SAL-0951 placebo: 1. initial phase:4mg QD for 8 weeks 2. subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in mean Hb concentration levels from baseline at weeks 7-9Time frame: Baseline and week 7-9
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.